Skip to main content

CAR-T cell therapy: genetically engineered T cells for the treatment of cancer

IRB Barcelona BioMed Seminars
7 May 21

Speaker: Sonia Guedan, PhD. –  IDIBAPS. Barcelona

Image

Presentation

Organizer: IRB Barcelona

Date: Friday 07 May 2021, 12.00h

Title: "CAR-T cell therapy: genetically engineered T cells for the treatment of cancer"

Host: Roger Gomis, PhD. Growth Control and Cancer Metastasis Lab-  Cancer Science Programme - IRB Barcelona

Abstract
The genetic engineering of T-cells to express chimeric antigen receptors, known as CAR-T cell therapy, has shown tremendous promise for the treatment of hematologic cancers. Five CAR-T cell therapies have been FDA-approved since 2017 for the treatment of leukaemia and lymphoma, marking a new era in oncology. However, the success of CAR-T cells in the context of hematologic malignancies has not translated yet into the setting of solid tumours. Although CAR-T cells are able to infiltrate solid tumors and exert antigen directed activity, sustained objective responses are rarely observed. Significant challenges remain with regard to understanding the factors that impact effective T cell persistence and function, especially in the context of solid tumors. New approaches to enhance the persistence and efficacy of CAR-T cells will be presented, with a focus on strategies to diminish T cell exhaustion and to prevent tumor escape due to immunosuppression or loss of antigen expression.

 

Biomed Webinar

Open to predoctoral UPF students

If you are interested in participating please send an email to cristina.mendez@irbbarcelona.org